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Available online 7 March 2019Background: Efﬂux pumps mediate antimicrobial resistance in several WHO critical priority bacterial pathogens.
However, most available data come from laboratory strains. The quantitative relevance of efﬂux inmore relevant
clinical isolates remains largely unknown.
Methods:We developed a versatile method for genetic engineering in multi-drug resistant (MDR) bacteria, and
used this method to delete tolC and speciﬁc antibiotic-resistance genes in 18 representative MDR clinical E. coli
isolates. We determined efﬂux activity and minimal inhibitory concentrations for a diverse set of clinically rele-
vant antibiotics in these mutants. We also deleted oprM inMDR P. aeruginosa strains and determined the impact
on antibiotic susceptibility.
Findings: tolC deletion abolished detectable efﬂux activity in 15 out of 18 tested E. coli strains, and modulated an-
tibiotic susceptibility in many strains. However, all mutant strains retained MDR status, primarily because of
other, antibiotic-speciﬁc resistance genes. Deletion of oprM altered antibiotic susceptibility in a fraction of clinical
P. aeruginosa isolates.
Interpretation: Efﬂuxmodulates antibiotic resistance in clinicalMDR isolates of E. coli and P. aeruginosa. However,
when other antimicrobial-resistance mechanisms are present, inhibition of MDR efﬂux pumps alone is often not
sufﬁcient to restore full susceptibility even for antibiotics with a dramatic impact of efﬂux in laboratory strains.
We propose that development of novel antibiotics should include target validation in clinical MDR isolates.
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Multi-drug resistant (MDR) Gram-negative bacterial pathogens rep-
resent a major global threat to human health. MDR pathogens drive
clinical usage of last-resort antibiotics such as carbapenems and colistin
further amplifying resistance development and the emergence of pan-
resistant pathogens [1]. As a consequence, deaths attributable to antimi-
crobial resistance may rise sharply, although the global burden of MDR
remains difﬁcult to estimate [2]. Resistance is multi-factorial but one
promiscuous mechanism covering diverse antibiotic classes is thestrasse 50/70, CH-4056 Basel,
.
. This is an open access article underexpression of so-called resistance-nodulation-division (RND) super-
family exporters, whichmediate active efﬂux of small molecules includ-
ingmany antibiotics from the periplasm and the innermembrane to the
extracellular environment [3–6]. RND efﬂux systems are tripartite com-
plexes of an inner membrane pump that is driven by the proton-motive
force, a periplasmic adapter protein and an outer membrane channel
[3–6]. Escherichia coli has multiple RND efﬂux systems with different
pumps and adaptor proteins, but all depend on a single outer mem-
brane efﬂux protein, TolC [7]. Pseudomonas aeruginosa has 18 different
RND efﬂux systems, and the major outer membrane efﬂux protein
OprM is required for resistance to a wide variety of antibiotics under
standard conditions, although overexpressed OpmJ or OmpH can re-
place OprM [7]. In laboratory strains of various Gram-negative bacterial
pathogens, upregulation of RND efﬂux systems increases resistance tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
We searched Pubmed and Google Scholar using the search terms
‘efflux’ and ‘antibiotics’ and ‘resistance’ for articles published up to
September 1st, 2018. Multiple studies have shown that genetic
inactivation of efflux in laboratory strains of E. coli and
P. aeruginosa dramatically increases their susceptibility to ap-
proved antibiotics that are active exclusively against Gram-
positive bacteria. If this key role of efflux also applies to more rel-
evant multi-drug resistant (MDR) clinical isolates remains uncer-
tain, since available genetic methods are cumbersome for such
isolates. Alternative methods such as efflux inhibitors yield incon-
clusive results because of their pleiotropic effects and limited
activity.
Added value of this study
This study seeks to quantify the impact of efflux in multi-drug re-
sistance of WHO critical priority 1 pathogens. It demonstrates
the utility of a versatile genetic method for generating mutants in
multi-drug resistant clinical isolates, and reveals an only moderate
contribution of efflux to antimicrobial resistance in clinical isolates
of E. coli and P. aeruginosa.
Implications of all the available evidence
Whilst results from laboratory strains suggest efflux as a poten-
tially useful target for novel antimicrobials, this study shows that
inhibiting efflux might have limited impact on clinically relevant
multi-drug resistant strains of E. coli and P. aeruginosa. These
data demonstrate the importanceof target validation in clinical iso-
lates in addition to analysis of laboratory strains.
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mutants hypersensitive [3–6]. Overexpression of RND efﬂux systems is
observed in many MDR clinical isolates suggesting that efﬂux might
be involved in increasing resistance [8].
Importantly, several key antibiotics including macrolides, various
tetracyclines, and fusidic acid are clinical effective against Gram-
positive pathogens, but fail against Gram-negative bacteria primarily
because of efﬂux [5,9]. Based on these observations, academia and in-
dustry have devoted major efforts to develop efﬂux inhibitors, hoping
that such compounds could break the intrinsic resistance of Gram-
negative bacteria against these already approved drugs [9]. However, al-
most all evidence for the impact of efﬂux comes from laboratory strains.
In contrast to these strains, clinicalMDR isolates evolve fromdiverse ge-
netic backgrounds, acquire speciﬁc antibiotic-resistance determinants,
upregulate various efﬂux pumps, and diminish outermembrane perme-
ability. All these changes, as well as additional poorly characterized
physiological differences, can inﬂuence the impact of efﬂux [10–12].
The quantitative contribution of efﬂux in clinical MDR isolates re-
mains still largely unclear [3–6,13]. Common methods for genetically
inactivating efﬂux are often cumbersome for MDR clinical strains [13].
Previous studies used suchmethods to determine the impact of a single
RND efﬂux pump (AcrB-AcrA-TolC) in various Escherichia coli isolates,
and a single or multiple RND efﬂux pumps in few Pseudomonas
aeruginosa isolates [13–18]. Efﬂux inhibitors are widely used to assess
efﬂux contributions in clinical strains, and often show only moderate
impact on resistance [18–22]. However, available inhibitors block efﬂux
in a substrate-dependent manner and inhibition might be incomplete
when used at low concentrations, especially in clinical MDR strains,
thus underestimating the role of efﬂux [5,6]. At high concentrations,these inhibitors have pleiotropic effects on cell envelope integrity and
overall bacterial physiology, impairing conclusive interpretation [5].
Efﬂux gene expression and sequences can be readily determined, but
overexpression and sequence polymorphisms of these genes poorly
correlate with resistance levels in clinical isolates [23,24].
Here, we developed a method to generate genetically deﬁned efﬂux
mutants in diverse MDR isolates, as part of the Innovative Medicines Ini-
tiative (IMI) Translocationproject [25].Weapplied themethod todiverse
MDR clinical isolates of twomajor pathogens on theWHO priority list of
particularly serious threats [1,26], Escherichia coli [27] and Pseudomonas
aeruginosa [28].Wedeletedgenes encoding crucial outermembrane sub-
units ofmultipleRNDpumps for extensivedisruptionof efﬂux, anddeter-
mined the impact on efﬂux activity and antibiotic susceptibility.
2. Methods
2.1. Whole-genome sequencing and analysis
Escherichia coli clinical isolates were grown on plates overnight and
colonieswere re-suspended inPBS.DNAwasextractedafter lysozymedi-
gestion at 37 °C for 15 min using a Maxwell 16 DNA extraction device
(Promega, Mannheim, Germany). Bacteria were treated with lysis buffer
containing Proteinase K and RNase for 1 h at 65 °C and DNA puriﬁcation
was performed as described by the manufacturer. After quality control
of the DNA, a fragmentation library was generated as described by the
manufacturer (NexteraXT kit, Illumina, San Diego, CA, USA). The ge-
nomeswere sequenced asmultiplexed samples using a 2×300 bpV3 re-
actionkit onan IlluminaMiSeq instrumentusing300bppairedendmode
to obtain an average coverage of approximately 70-fold for all isolates.
After quality control, reads were quality trimmed and downstream anal-
ysis was carried out using CLC Genomics Workbench (Qiagen) and
SeqSphere+ (Ridom). Reads were mapped to the reference Escherichia
coli ATCC 25922 genome (GenBank: CP009072.1 (ATCC 25922) and
1855 genes belonging to the common core genome were analyzed for
their allelic differences (core genome Multilocus Sequence Typing,
cgMLST [29,30]). Multi-locus sequence types (MLST) were determined
using the web server available at https://cge.cbs.dtu.dk//services/MLST/
using typing scheme (“MLST conﬁguration”) Escherichia coli#1 [31]. Ac-
quired antibiotic resistance genes were identiﬁed using the database
ResFinder [32]. Chromosomal point mutations associated with antibiotic
resistance were identiﬁed usidng PointFinder [33]. To close plasmid se-
quences, we sequenced isolates EC03 and EC11 also with MinION using
the 1D barcoded library preparation kit (EXP-NBD103, Oxford Nanopore
Technologies) according to the manufacturer's protocol.
2.2. Gene deletion in clinical isolates
The choice of positive selectionmarkers for theﬁrst recombination is
severely limited for multi-drug resistant isolates, in which most stan-
dard antibiotic resistance cassettes confer no additional selectable phe-
notype. However, almost all our isolateswere sensitive to the potassium
salt of the tellurium oxyanion tellurite (TeO32−) at concentrations of
50 mg l−1 (E. coli) or 200 mg l−1 (Pseudomonas aeruginosa). This en-
abled us to use a thiopurine-S-methyltranferase (tpm, ACIAD2922)
from Acinetobacter baylyi as a positive selectionmarker that reduces tel-
lurite to intracellular metallic tellurium (detectable as black colony col-
our), and might also convert tellurite into volatile dimethyl telluride
[34]. In E. coli, tpm expression from the rpsL promoter of Burkholderia
cenocepacia was sufﬁcient to yield tellurite resistance. To obtain high-
level resistance in P. aeruginosa, we expressed tpm from the strong con-
stitutive pX2 promoter [35]. It was important to use exponentially
growing Pseudomonas for selection, as initially non-growing cells
could eventually form colonies on tellurite plates even without the re-
sistance cassette. Often we got both small and large colonies, the latter
of which were more likely to carry the tpm cassette. We puriﬁed
transconjugants by restreaking. For negative selection,we used classical
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Fig. 1.Genome diversity of clinical Escherichia coli strains and gemedeletion plasmid. (a,b)
Analysis of clinical MDR Escherichia coli strains by whole genome sequencing. (b) Tree
illustrating the relationship between 18 strains for which we could obtain ΔtolC
mutants, based on the cgMLST (core genome multi-locus sequence typing) allelic
proﬁles. The scale bar represents 200 allelic differences. The tree is colored according to
MLST sequence types (STs). Strains EC19 to EC24, for which were unable to obtain ΔtolC
mutants are marked with asterisks. (c) Occurrence of acquired antimicrobial resistance
genes as detected by ResFinder [32] and chromosomal point mutations (ChrPM)
associated with antimicrobial resistance as identiﬁed by PointFinder [33]. (c) Plasmid for
deleting genes in MDR bacterial pathogens. The plasmid carries the R6K γ origin of
replication which depends on the replication protein π (encoded by pir) which is absent
in almost all clinical strains; tpm encoding thiopurine-S-methyltranferase, which confers
resistance to tellurite (most MDR clinical isolates are sensitive to tellurite); the origin of
conjugational transfer oriT; traJ encoding the transcriptional activator for conjugational
transfer genes; sacB encoding levansucrase, which confers sensitivity to sucrose. The
hatched regions ﬂ-up and ﬂ-do represent ﬂanking regions of the target gene for deletion.
The hooked arrows represent promoters.
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in NaCl-free media [36].
We used E. coli JKE201 expressing the protein π (the initiator protein
for R6K) for propagating and conjugation of the R6K-containing plas-
mids. Like its parental strain MFDpir [37], JKE201 is free from bacterio-
phage Mu. This phage is present in commonly used E. coli donor
strains such as SM10λpir posing a risk of phage contamination of ex-
conjugants [37]. JKE201 (like MFDpir) also carries a dapA deletion con-
ferring auxotrophy to diaminopimelic acid (DAP), which permits facile
counter-selection in absence of DAP to obtain donor-free ex-
conjugants. As additional features, apramycin/gentamicin resistance
cassette and all three type IV restriction endonucleases as well as the
type I restriction/modiﬁcation EcoKI have been removed in JKE201 to
improve cloning of PCR-ampliﬁed DNA fragments (genotype: MG1655
RP4-2-Tc::[ΔMu1::Δaac(3)IV::lacIq-ΔaphA-Δnic35-ΔMu2::zeo] ΔdapA::
(erm-pir) ΔrecA ΔmcrA Δ(mrr-hsdRMS-mcrBC)) [38].
Plasmids carrying a fusion of 700 bp ﬂanking regions of the gene of
interest as well as a tellurite resistance cassette and sacB and the π-
dependent R6K origin of replication (which cannot propagate in
P. aeruginosa and E. coli), were constructed using Gibson assembly [39]
and transferred into JKE201 by heat shock. Transformantswere selected
on LB agar plates containing 10 mg l−1 potassium tellurite and 100 μM
2,6-diaminopimelic acid. Plasmids were sequenced, and conﬁrmed
transformants were mated with clinical E. coli or P. aeruginosa strains
on ﬁlters with 0·45 μm pores. Ex-conjugants were incubated for at
least one hour in fresh LB before selection on LB plates containing
50 mg l−1 (E.coli) or 200 mg l−1 (P. aeruginosa) potassium tellurite.
Ex-conjugants were validated by PCR and correct clones were grown
in liquid LB to exponential phase and selected on agar plates containing
NaCl-free LB and 20% (E. coli) or 10% (P. aeruginosa) sucrose. Deletion
mutants were validated by PCR and conﬁrmed by sequencing.
In several cases, this procedure rapidly yielded the desired deletion
mutants. For many other strains, however, there was a strong bias for
both single cross-overs to occur at the same ﬂanking region thus restor-
ing the wild-type locus instead of the desired deletion. Which ﬂanking
regionwas preferred differed from isolate to isolate andwas apparently
unrelated to the endogenous sequence of these ﬂanking regions as de-
termined by whole genome sequencing. In many cases, we could solve
this problem by PCR-screening for rare clones that had used the non-
preferred site for the ﬁrst single cross-over. Such clones often resolved
using the preferred region yielding the desired gene deletion mutant.
Plasmids of two E. coli strains were cured by inserting both tpm and
sacB followed by extensive positive and negative selection rounds. One
of the two strains, EC03, contained a plasmid with 99·95% sequence
identity to previously characterized pH 105 [40]. Plasmid loss was veri-
ﬁed by whole-genome sequencing.
2.3. Efﬂux assay
We determined efﬂux activities using a Nile Red assay as described
[41]. In brief, E. coli overnight cultures in lysogeny broth (37 °C)were in-
cubated with 10 μM carbonyl cyanidem-chlorophenylhydrazone and 5
μMNile Red for 3 h at 37 °C and 1 h at room temperature. The cells were
centrifuged, resuspended in buffer (1 mM MgCl2, 20 mM potassium
phosphate, pH 7·0), transferred to a 96-well plate, and placed in a
plate reader (Synergy H4, BioTek). Fluorescence (excitation at 552 nm,
emission 636 nm) was followed for 120 s. Nile Red efﬂuxwas then trig-
gered by rapid energization with 50 mM glucose and monitored for an-
other 300 s to detect even rather slow efﬂux.
3. Results
3.1. Gene deletion in clinical Escherichia coli isolates
We selected 24 E. coli clinical isolates from patient blood, sputum,
surface swabs, urine, or fecal samples. All isolates were non-susceptible to agents of three or more antimicrobial categories thus ful-
ﬁlling the standard deﬁnition for MDR status [42]. Whole genome se-
quencing revealed that these isolates were genetically diverse with
hundreds of allelic differences, covered seven different multi-locus se-
quence types (STs) with the expected dominance of ST 131 [43]
(Fig. 1a), and carried various resistance determinants (Fig. 1b). Taken
together, these data demonstrate that our collection is representative
of diverse, clinically relevant MDR E. coli strains.
We developed a method combining various previously described
components, to facilitate efﬁcient generation of genetically deﬁned ef-
ﬂux mutants in these isolates. We employed a suicide plasmid
(Fig. 1c) and two consecutive single cross-overs. We used thiopurine-
S-methyltranferase Tpm conferring resistance to tellurite [44], as posi-
tive selection marker that works even in MDR isolates. Tellurite resis-
tance has been previously used as positive marker [45–48]. We used
levansucrase SacB conferring susceptibility to sucrose as negative selec-
tion marker. We accelerated plasmid construction using rapid Gibson
assembly [39]. We transformed the plasmids into E. coli JKE201 [38] as
482 O. Cunrath et al. / EBioMedicine 41 (2019) 479–487a donor for conjugation. This strain that was free of commonly encoun-
tered phages that could infect clinical isolates and distort mutant phe-
notypes [37]. For efﬁcient selection of ex-conjugants against donor
cells, we exploited the fact that JKE201 lysed without supplementation
of diaminopimelic acid. We realized that gene deletion often failed
when there was a strong bias for recombination in one of the two
ﬂanking regions. As both the ﬁrst and the second single cross-over oc-
curred in the same preferred region, we mostly got reversion back to
wild-type, instead of the desired deletion. To mitigate this problem,
we determined in which ﬂanking region the ﬁrst single cross-over oc-
curred using PCR with primers binding to upstream and downstream
sequences aswell as primers binding to plasmid sequences.We then se-
lected rare ex-conjugants in which the ﬁrst cross-over had occurred in
the non-preferred region, and used them for subsequent selection for
second cross-over. This yielded desired deletion mutants at increased
rates.
To determine the contribution of efﬂux, we aimed at deleting tolC,
which encodes the outer membrane channel required for the function
of all known E. coli RND efﬂux systems [7]. For ﬁve strains, we could ob-
tain cleandeletions of tolCwithin three days,while for the otherswe ob-
tained plasmid insertions that reverted to wild-type upon the second
cross-over in all tested clones. We repeated the conjugations and got
seven additional mutants. For additional rounds, we speciﬁcally worked
with ex-conjugants with non-preferred insertions sites, which yielded
sixmoremutants in three attempts. Together, we obtained tolCmutants
for 18 out of 24 E. coli clinical isolates. For six isolates, we did not detect
the desired deletion even after screening up to 296 different colonies
from ﬁve independent attempts. However, sequence types and resis-
tance gene patterns of these isolates were largely represented by the
18 successfully manipulated strains (Fig. 1a,b). We therefore did not
put further efforts into generating mutants for the six failed isolates.
All tolC deletions were conﬁrmed by sequencing.
3.2. Efﬂux activities of E. coli ΔtolC mutants
To determine efﬂux activities of E. coli isolates and their respective
tolCmutants, we used a Nile Red-based assay [41] that is especially suit-
able for comparing efﬂux in diverse isolates [49] (Fig. 2a,b; Supplemen-
tary Table 1). Seventeen E. coli isolates showed rapid efﬂuxwith kinetics
in the range of previously reported data [41] (a representative examples
is shown as black line in Fig. 2a). Deletion of tolC totally abolished efﬂux
in 15 strains and dramatically slowed down efﬂux in two other strains
(Fig. 2a,b). The molecular mechanism of residual slow glucose-
dependent Nile Red ﬂuorescence loss in these two tolCmutants remain
unknown, but may involve outer membrane efﬂux proteins that could
partially compensate for TolC [50], or other efﬂux mechanisms that do
not depend on a particular outer membrane efﬂux protein. EC18 and
EC18 ΔtolC showed declining ﬂuorescence signals in energy-depleted
cells even before re-energization with glucose, preventing quantitative
analysis of energy-dependent efﬂux (dotted blue and orange lines in
Fig. 2a). Together, our data indicate complete inactivation of efﬂux
upon tolC deletion in 15 out of 18 clinical isolates.
3.3. Antibiotic susceptibility of E. coli ΔtolC mutants
We tested the strains for susceptibility to therapeutically relevant
antimicrobials according to EUCAST (European Committee on Antimi-
crobial Susceptibility Testing. Breakpoint tables. Version 9.0, 2019)
using commercial phenotyping systems (Vitek 2 and E-tests, bio-
Mérieux). We represent the data as minimal inhibitory concentrations
that prevent growth (MIC) (Fig. 2c,d; Supplemental Table 1). High
MIC values correspond to probable clinical treatment failures
(“resistant”).
We ﬁrst tested three antibiotics with potent Gram-positive antibac-
terial activity, but poor activity against Gram-negative bacteria (doxycy-
cline, erythromycin, and fusidic acid). Previous studies showed that inE. coli laboratory strains, intrinsic resistance against these compounds
is mainly caused by RND efﬂux pumps [5,9]. We conﬁrmed these ﬁnd-
ings for a ΔtolC mutant of the laboratory strain E. coli K-12 MG1655
that showed eightfold, tenfold, and more than 64fold lower MIC values
compared to parenteral MG1655 (ﬁrst arrows in each panel of Fig. 2c).
ΔtolCmutants of several MDR E. coli clinical isolates also became more
susceptible (Fig. 2c). For these three drugs, susceptibility breakpoints
for E. coli and PK/PD breakpoints are not available. Based on EUCAST
breakpoints for Gram-positive bacterial pathogens as tentative ﬁrst ap-
proximations, several ΔtolCmutants might indeed have become sensi-
tive to clinically achievable doxycycline or erythromycin
concentrations (hatched blue area). Breakpointsmight also differ some-
what for efﬂux-inhibited E. coli as compared to Gram-positive bacteria.
Surprisingly, however, several other mutants retained high resistance
well above putative breakpoints. As most of these mutants showed no
detectable efﬂux activity (Supplemental Table 1), they might possess
other resistance mechanisms.
Deletion of tolC in MDR E. coli isolates had some impact on MIC
values of antibiotics that are active against Enterobacteriaceae
(Fig. 2d). The effect size was generally lower or similar to what has
been observed for fully susceptible laboratory strains [3–6], and almost
always too small to convert resistant strains into susceptible ones (i.e., a
shift from red to blue areas).We had expected larger effects since many
clinical strains show increased expression of RNDpumps, anddecreased
outermembrane permeability, which can further enhance the impact of
efﬂux [10–12]. Several strains showed very highMIC values beyond the
detection range of the phenotyping systems. In these cases, deletion of
tolC might have made the strains more susceptible without being no-
ticed. However, such changes would be still far from clinically relevant
concentrations. For β-lactam antibiotics (alone or in combination with
β-lactamase inhibitors), changes occurred sometimes in the opposite
direction (i.e., gettingmore resistant) as previously reported in an efﬂux
inhibitor study [51]. This could be a consequence of pleiotropic effects of
efﬂux inactivation.
The only exceptions with substantial loss of resistance at least
against some antibiotics were isolates EC08, EC10, EC14, and EC17.
EC10 became susceptible to the aminoglycosides tobramycin and
amikacin, and trimethoprim-sulfamethoxazole, upon tolC deletion
(thick blue arrows in Fig. 2d). Interestingly, EC10 was the only isolate
that showed resistance to these drugs but lacked antibiotic-speciﬁc re-
sistance determinants (such as aac(6′)-Ib and aac(6′)-Ib-cr encoding
aminoglycoside modifying enzymes, of dfrA alleles and sul alleles resis-
tant to trimethoprim or sulfamethoxazole, respectively; Fig. 1b). This
apparent lack of speciﬁc resistance mechanisms would be compatible
with an important role of general mechanisms such as efﬂux, although
aminoglycosides have not yet been found to be relevant substrates for
RND efﬂux systems in E. coli. Trimethoprim might directly interact
with RND pumps [52]. On the other hand, EC10 ΔtolC remained resis-
tant to agents in three antimicrobial categories and thus retained MDR
status. Another mutant, EC08 ΔtolC, showed diminished MIC for
amikacin (MIC 4 mg l−1) but retained tobramycin resistance. Under
these circumstances, the amikacin MIC may not be a reliable predictor
of clinical activity [53] and the strain should be reported as “intermedi-
ate” for amikacin according to EUCAST rules [54] (dotted blue arrow in
Fig. 2d). Strains EC14 and EC17 became susceptible to ciproﬂoxacin
upon tolC deletion. Common chromosomal gyrA target mutations con-
ferring ﬂuoroquinolone resistance were absent in these two isolates
(Fig. 1c).
3.4. Role of efﬂux-independent mechanisms
The modest impact of efﬂux inactivation in many clinical isolates
was initially surprising, but did not necessarily indicate a minor role of
efﬂux. Inactivating TolC can cause pleiotropic side effects including sup-
pression of outermembrane porin F (OmpF) [7,51,55,56]. Such pleiotro-
pic effects might provide compensatory resistance mechanisms not
Fig. 2. Impact of genetic inactivation of efﬂux on antimicrobial susceptibility inMDR E.coli. (a,b) Efﬂux activities in clinical isolates and corresponding ΔtolCmutants. (a) Energy-depleted
cellswere loadedwith Nile red. Cellswere then re-energizedwith glucose (arrow, 120 s), and efﬂuxwasmeasured as decrease inNile redﬂuorescence (which is lower in aqueous solution
compared to bacterial membranes). All isolates except EC18 showed rapid energy-dependent efﬂux (representative example shown in black), whereas all ΔtolCmutants showed no, or
much slower, ﬂuorescence loss upon energization (examples shown as dashed black ormagenta lines). EC18 (blue dotted line) and itsΔtolCmutant (orange dotted line) lost ﬂuorescence
in an energy-independent manner (i.e., even prior to glucose addition) preventing quantitative analysis of efﬂux. Representative traces for the laboratory strain K-12 and itsΔtolCmutant
are shown for comparison (grey lines). (b) Time intervals after energization until 50% of ﬂuorescence intensity was lost. Time resolution preventedmeasurement of half-times below 10 s
(dotted line) or above 300 s (dashed line). (c,d)Minimal inhibitory concentrations that prevent growth (MICs) of Escherichia coli isolates and correspondingΔtolCmutants. Data are shown
for drugs that are normally ineffective against Escherichia coli (c), and for common therapeutically used antimicrobials (d). Crosses represent values for parental isolates. The impact of
ΔtolC deletion is represented by arrows. If there is no arrow, the mutant MIC remained at the parental level. MIC ranges corresponding to clinical resistance (red) or susceptibility
(blue) according to EUCAST breakpoints are shown as background. Breakpoints shown in (c) are estimates based on values for other bacterial pathogens. MIC values outside themeasure-
ment range are shown as shaded areas. The thick blue arrows mark conversion of clinical resistance to susceptibility as a result of genetic inactivation of major efﬂux systems, while the
dotted blue line for EC08 and amikacin should still be reported as “intermediate” (see text). K-12 had MIC values below the lowest measured concentration (shaded blue regions) for all
antibiotics shown in (d). (e,f) Impact of additional inactivation of speciﬁc resistance determinants in efﬂux-deﬁcient strains. (e) Comparison of susceptibility of parental strains, theirΔtolC
mutants, and variousdoublemutants (AMC, Amoxicillin/Clavulanic acid; SXT, Trimethoprim-sulfamethoxazole).We determined susceptibility to ciproﬂoxacinusing a brothmicrodilution
technique to cover the nanomolar concentration range. (f) Antimicrobial spectrum changes in doublemutants (blue, switch from “resistant” or “intermediate” in the tolCmutant to “sus-
ceptible” in the double mutant; white, “susceptible” unaltered; red, “resistant” unaltered; CAZ, Ceftazidime; CIP, Ciproﬂoxacin; CRO, Ceftriaxone; DOX, Doxycycline; FEP, Cefepime; TOB,
Tobramycin; TZP, Piperacillin/Tazobactam). The blue crosses indicate resistance mechanisms that were speciﬁcally inactivated in each of the four double mutants.
483O. Cunrath et al. / EBioMedicine 41 (2019) 479–487
484 O. Cunrath et al. / EBioMedicine 41 (2019) 479–487present in the wild-type isolates such as restricting drug entry through
OmpF [57], thus replacing efﬂux with little overall change in MIC. This
was suggested as a possible explanation for increased resistance to β-
lactams upon efﬂux inhibition in Salmonella [51]. Alternatively, the
non-impressive ΔtolC phenotypes could be due to the large sets of
antibiotic-modifying enzymes, acquired antibiotic-resistant
target alleles such as dfrA14, and/or mutated chromosomal target
genes such as gyrAS83L D87N (Fig. 1b). To determine the quantitative con-
tributions of efﬂux/compensatory side effects vs. efﬂux-independent
antibiotic-speciﬁc mechanisms, we constructed double mutants in iso-
lates from three different E. coli sequence types.
To inactivate multiple resistance mechanisms simultaneously, we
cured plasmids carrying multiple antibiotic-modifying genes and ac-
quired antibiotic-resistant target alleles (Fig. 3) in two strains yielding
double mutants EC11 ΔtolC pEC11− and EC03 ΔtolC pH 105−. We con-
structed two additional double mutants in which a single resistance de-
terminant was targeted: EC13 ΔtolC ΔdfrA14 with potentially restored
susceptibility to trimethoprim; and EC06 ΔtolC gyrAL83S N87D with po-
tentially restored susceptibility to ciproﬂoxacin. This combined inacti-
vation of efﬂux and antibiotic-speciﬁc mechanisms led to full
susceptibility to one or several of the six tested clinically relevant anti-
microbial categories in strict concordance with the respective targeted
mechanisms (Fig. 2e,f). These data indicated that the tolC deletion,
which was present in each double mutant, did not have compensatory
side effects that would confer clinically relevant resistance to the tested
antibiotics. By contrast, antibiotic-speciﬁcmechanismswere crucial. To-
gether, this evidence suggested that inhibiting RND efﬂux alone was
largely insufﬁcient to break MDR of E. coli clinical isolates, even in case
of antibiotics with Gram-positive activity such as doxycycline that
were thought to lack Gram-negative activity primarily because of efﬂux.
3.5. Antibiotic susceptibility of P. aeruginosa ΔoprM mutants
We also selected several MDR P. aeruginosa isolates from four differ-
ent Belgian hospitals [58] that had divergent serotypes, antibiograms
and efﬂux pump expression patterns (Fig. 4a–d; Supplemental
Table 2). In seven out of 12 tested P. aeruginosa strains, we were able
to delete oprM encoding the outer membrane channel of major efﬂuxsul1
aadA5
dfrA17
qacE 1 mph
TXSTXS
pEC11
mrxsul1
aadA5
dfrA17
mphR mphA
ermC
TXSTXS
pH105
Fig. 3. Plasmid-encoded antimicrobial resistance genes. Gene clusters that contained all detecte
plasmid sequence of 148,945 bp are shown) and EC03 (pH 105; 20,000 bp of a total plasmid l
relevant antibiotics that were tested in this study (AMC, Amoxicillin/Clavulanic acid; CAZ,
sulfamethoxazole SXT; TOB, Tobramycin). AAC(6′)-Ib-cr can modify both tobramycin and
remained below the EUCAST breakpoint (Fig. 2d). Similar ﬁndings have been obtained for man
resistance to ciproﬂoxacin [65], but in EC11 which carries also a high-resistance chromosomal
overall ciproﬂoxacin resistance. Gene names in black indicate other resistance genes. Transpossystems MexAB and MexXY (except for rare isolates of the taxonomic
outlier PA7 group [59], in which MexXY uses OprA), as well as minor
systems MexMN, MexVW, and partially MexJK. For some extensively
MDR P. aeruginosa isolates, there was a high background growth even
at 200 mg l−1 tellurite hampering positive selection for ex-conjugants.
All mutants were veriﬁed by sequencing.
We ﬁrst tested two antibiotics that are active against other bacteria,
but fail against P. aeruginosa (tigecycline and azithromycin). In
P. aeruginosa laboratory strains, inactivation of a single OprM-
dependent efﬂux pump, MexAB breaks this intrinsic resistance [5], sug-
gesting that efﬂux inhibition could extend the spectrumof these already
approved antibiotics to P. aeruginosa. In several of our clinical MDR iso-
lates, oprM deletion indeed increased sensitivity to both antibiotics
(Fig. 4b). Based on EUCAST breakpoints for Enterobacteriaceae as tenta-
tiveﬁrst approximation, severalΔoprMmutants became almost suscep-
tible (hatched blue area). Some strains also showed substantial
sensitization to azithromycin. Since MIC values in standard Müller-
Hinton broth might underestimate clinical efﬁcacy [60], efﬂux inhibi-
tion could be sufﬁcient for therapeutic potency also for this antibiotic
and these particular strains. Breakpoints might differ somewhat for
efﬂux-inhibited P. aeruginosa compared to Enterobacteriaceae and
Gram-positive bacteria. However, unexpectedly, several of ΔoprMmu-
tants of our clinical strains retained high resistance well above putative
breakpoints for both antibiotics even after inactivation of efﬂux.
In several strains, deletion of oprM had remarkable effects for aztre-
onam (which is rarely used against this pathogen because of often high
MIC values [61]) and a ceftazidime / avibactam combination that was
approved in 2015, after isolation of the P. aeruginosa strains used in
this study [58] (Fig. 4c). The latter data supported a previously sug-
gested partial contribution of efﬂux in pre-existing resistance against
this new drug combination [62].
MDR P. aeruginosa ΔoprMmutants showed mostly non-impressive
alterations in susceptibility to antibiotics with anti-pseudomonal activ-
ity. These data extend observations from a previous study, in which six
strains from an industrial collection showed moderate impact of oprM
inactivation on high resistance to anti-pseudomonal antibiotics [18].
Strain PA256 ΔoprM had a diminished MIC value for amikacin
(6 mg l−1) but remained resistant to tobramycin. Under theseblaCTX-M-27tet(A)tetRmrx
R mphA aph(3'')-Ib
sul2
aph(6)Id
ZACTXS
CRO
FEP
DOX
catB3
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TOBDOX
d antimicrobial resistance genes on plasmids present in EC11 (pEC11; 30,000 bp of a total
ength of 134,920 bp). Gene names in red indicate genes conferring resistance to clinically
Ceftazidime; CRO, Ceftriaxone; DOX, Doxycycline; FEP, Cefepime; SXT, Trimethoprim-
amikacin. However, strain EC11 was only resistant to tobramycin while amikacin MIC
y Enterobacteriaceae that possess AAC(6′)-Ib [53]. AAC(6′)-Ib-cr can also cause low-level
gyrAS83L D87N allele (Fig. 1c), AAC(6′)-Ib-cr likely provided only a modest contribution to
able elements are shown in blue, and other genes are grey.
Fig. 4. Impact of oprM deletion on MDR P. aeruginosa clinical isolates. (a) Strain characteristics of highly resistant Pseudomonas aeruginosa clinical isolates (n.d., not detected). (b,c,d)
Minimal inhibitory concentrations that prevent growth (MICs) of clinical P. aeruginosa strains and their ΔoprM mutants. The laboratory strain UCBPP-PA14 (PA14) and its ΔoprM
mutant are shown for comparison. Data represent drugs that are ineffective against P. aeruginosa (a), that are rarely used or only recently approved (b) (Ceft. / Avib., Ceftazidime /
Avibactam), or commonly used against P. aeruginosa (c). Crosses represent values for parental isolates. The impact of oprM deletion is represented by arrows. If there is no arrow, the
mutant MIC remained at the parental level. MIC ranges corresponding to clinical resistance (red) or susceptibility (blue) according to EUCAST breakpoints are shown as background.
MIC values outside the measurement range are shown as shaded areas. Breakpoints shown in (b) are estimates based on values for other bacterial pathogens. The thick blue arrows
mark conversion of clinical resistance to susceptibility as a result of genetic inactivation of major efﬂux systems, while the dotted blue line for PA256 and amikacin should still be
reported as “resistant” (see text). MIC values outside the measurement range are shown above the highest tick, or below the lowest tick, respectively.
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ical activity, and the strain should be reported as “resistant” for amikacin
(dotted blue arrow in Fig. 4d).
Deletion of oprM inactivates the clinically most relevant RND efﬂux
systems in P. aeruginosa, MexAB and MexXY, which represent the pri-
mary targets for efﬂux inhibitor development programs against MDR
P. aeruginosa. In addition, P. aeruginosa encodes various other RNDefﬂux
systems that are independent of OprM [5]. It is possible that such other
efﬂux systems masked the effect of oprM deletion in some of our mu-
tants (as it has been shown for one single isolate of the rare PA7
group [17]), but the most important alternative pumps, MexCD-OprJ
or MexEF-OprN, were not overexpressed in our most refractory strains
142 and 256 (Fig. 4a). It might be challenging to develop promiscuous
but safe inhibitors/inhibitor combinations for all relevant P. aeruginosa
efﬂux systems, given the toxicity of several otherwise promising inhib-
itors [3–6,9].
4. Discussion
Our genetically deﬁned mutants show that major RND efﬂux sys-
tems contribute to intrinsic resistance against antibiotics with Gram-
positive activity, and to the MDR phenotype of many MDR clinical
E. coli and P. aeruginosa strains. However, the effects were only moder-
ate inmost isolates, and did not generally increase susceptibility to clin-
ically relevant levels. In several cases, additional mutagenesis revealed a
dominant impact of antibiotic-speciﬁc resistance determinants, whichmaintained high resistance levels even in absence of efﬂux. These data
are compatible with previous genetic studies for single RND efﬂux
pump (AcrB-AcrA-TolC) in various Escherichia coli isolates, or individual
or multiple RND efﬂux pumps in some Pseudomonas aeruginosa isolates
[13–18]. Studies employing efﬂux inhibitors also suggested often only
moderate impact on resistance in clinical isolates [18–22].
A number of our efﬂux mutants became susceptible to antibiotics
with exclusive Gram-positive activity as expected from data for labora-
tory strains. However, surprisingly, some mutants remained non-
susceptible suggesting additional resistance mechanisms. E. coli or
P. aeruginosamight carry suchmechanisms in spite of being already in-
trinsically resistant, for two potential reasons. First, even sub-lethal ex-
posure to antibiotics can provide sufﬁcient selection for evolution of
high-level resistance [63]. Second, large integrons carrying multiple re-
sistance determinants can be exchanged between Gram-positive and
Gram-negative bacteria, and this can include resistance determinants
such as tetAR, that might have adaptive roles predominantly in Gram-
positive bacteria. Laboratory strains, which most previous studies ana-
lyzed, had no recent opportunities for gene-exchange with Gram-
positive bacteria andnoprevious exposure to these antibiotics, resulting
in discrepancies in the role of efﬂux when compared to clinical MDR
isolates.
Taken together, our data do not generally support previous hopes for
broadening the spectrum of approved antibiotics to Gram-negative crit-
ical priority bacterial pathogens using efﬂux inhibitors, or for restoring
activity of other antibiotics [3,4]. These results thus argue against the
486 O. Cunrath et al. / EBioMedicine 41 (2019) 479–487main motivation for developing such inhibitors. On the other hand,
some strains did show substantial sensitization upon efﬂux inactivation.
If such strains could be rapidly identiﬁed in the clinics, efﬂux inhibitors
could ﬁnd some applications.
Our study has limitations and caveats. In particular, we investigated
several key classes of antibiotics in the two major pathogens that have
been at the focus of RND efﬂux research, but there might be some
other drug-bug combinations, for which efﬂux inhibitors could still be
useful, especially in case of entirely new compound classes. It is also im-
portant to note that some residual efﬂux activity might be mediated by
alternative outer membrane channels, especially in P. aeruginosaΔoprM
mutants. Some residual efﬂux might also still be present in E. coli ΔtolC
mutants, although the Nile Red efﬂux assay showed non-detectable ac-
tivities in most of our mutants. Inactivating the major RND outer mem-
brane channel is thus not necessarily the same as inhibiting efﬂux
completely. Efﬂux might also play an important role in strains with
only low-level resistance, which we did not study: However, this
would have limited relevance for solving the urgent MDR crisis.
Future studies could determine the role of efﬂux in clinical multi-
drug resistance in additional pathogens using the methods developed
in this study. Further research onRND efﬂux systems and their substrate
selectivity is essential to obtain a rational basis for developing efﬁca-
cious novel drugs that escape efﬂux. Efﬂux systems also contributes to
pathogen virulence [64] suggesting a potential role for efﬂux inhibitors
in anti-virulence strategies. Some efﬂux inhibitors have also antimicro-
bial properties [6], and could thus be valuable as starting points for
novel antibiotics.
In summary, this study shows a moderate contribution of efﬂux to
antimicrobial resistance in MDR clinical strains of theWHO top priority
pathogens E. coli and P. aeruginosa. More generally, we demonstrate the
importance of validating potential target genes in relevant clinical iso-
lates, in addition to studying well-characterized laboratory strains. Our
gene deletion method will be suitable for this purpose.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2019.02.061.
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